274 related articles for article (PubMed ID: 16158715)
1. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
2. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
Giannini EG; Kane SV; Testa R; Savarino V
Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
5. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
7. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
8. [Inflammatory bowel disease and colorectal cancer].
Hagymási K; Tulassay Z
Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
[TBL] [Abstract][Full Text] [Related]
9. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
Levine JS; Burakoff R
Inflamm Bowel Dis; 2007 Oct; 13(10):1293-8. PubMed ID: 17567870
[TBL] [Abstract][Full Text] [Related]
10. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
Munkholm P; Loftus EV; Reinacher-Schick A; Kornbluth A; Mittmann U; Esendal B
Digestion; 2006; 73(1):11-9. PubMed ID: 16410688
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
12. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
Bernstein CN; Eaden J; Steinhart AH; Munkholm P; Gordon PH
Inflamm Bowel Dis; 2002 Sep; 8(5):356-61. PubMed ID: 12479651
[TBL] [Abstract][Full Text] [Related]
13. Role of 5-aminosalicylate in preventing colorectal cancer.
Riyaz S; Hamlin J; Everett S
Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414
[No Abstract] [Full Text] [Related]
14. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
van Staa TP; Card T; Logan RF; Leufkens HG
Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
[TBL] [Abstract][Full Text] [Related]
15. Will a 5-ASA a day keep the cancer (and dysplasia) away?
Rubin DT; Lashner BA
Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
[TBL] [Abstract][Full Text] [Related]
16. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of colorectal cancer in inflammatory bowel disease.
Butterworth JR
Dig Liver Dis; 2009 May; 41(5):338-9. PubMed ID: 19268635
[No Abstract] [Full Text] [Related]
18. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Rubin DT; Cruz-Correa MR; Gasche C; Jass JR; Lichtenstein GR; Montgomery EA; Riddell RH; Rutter MD; Ullman TA; Velayos FS; Itzkowitz S;
Inflamm Bowel Dis; 2008 Feb; 14(2):265-74. PubMed ID: 17932965
[TBL] [Abstract][Full Text] [Related]
19. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
Herfarth H
Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
[TBL] [Abstract][Full Text] [Related]
20. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
